Takeda Pharmaceutical (TAK) Non-Current Debt (2018 - 2026)

Takeda Pharmaceutical's Non-Current Debt history runs 9 years deep, the most recent figure standing at $27.9 billion for Q1 2026.

• On a quarterly basis, Non-Current Debt rose 7.18% year-over-year to $27.9 billion in Q1 2026; TTM through Mar 2026 was $27.9 billion, a 7.18% increase from a year earlier, with the FY2026 full-year figure at $29.0 billion, up 11.48% from the prior year.
• Non-Current Debt improved to $27.9 billion in Q1 2026 per TAK's latest filing, from $26.0 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $35.6 billion in Q1 2022 and bottomed at $4.0 billion in Q1 2023.
• The 5-year median for Non-Current Debt is $26.0 billion (2025), against an average of $19.6 billion.
• Across the five-year window, Non-Current Debt soared 628.65% in 2022 and tumbled 88.67% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $35.6 billion in 2022, then tumbled by 88.67% to $4.0 billion in 2023, then climbed by 14.91% to $4.6 billion in 2024, then soared by 460.13% to $26.0 billion in 2025, then advanced by 7.18% to $27.9 billion in 2026.
• Per Business Quant, the three latest TAK Non-Current Debt figures stand at $27.9 billion (Q1 2026), $26.0 billion (Q1 2025), and $4.6 billion (Q1 2024).